Johnson & Johnson reported that global sales of Darzalex reached $4.239 billion during the third quarter of 2026, with significant revenues both in the US and internationally, benefiting Genmab through royalties under a licensing agreement. #JohnsonJohnson #Genmab #Läkemedel (translated)
www.di.se
Johnson & Johnson säljer mer av Genmabs läkemedel
